Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study.
MacIntyre
C R
CR
Kelly
H
H
Jolley
D
D
Butzkueven
H
H
Salmon
D
D
Halsey
N
N
Moulton
L H
LH
D015982:Bias; D016022:Case-Control Studies; D015984:Causality; D003627:Data Interpretation, Statistical; D016208:Databases, Factual / Q000592:standards; D006510:Hepatitis B Antibodies / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000009:adverse effects* / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects / Q000276:immunology; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects* / Q000276:immunology; D015203:Reproducibility of Results; D012189:Retrospective Studies; D006113:United Kingdom
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D011994:Recombinant Proteins